WS Canlife UK Equity Fund C AccumulationRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | -9.6 | 20.7 | -1.0 | 9.2 | 2.4 | |
+/-Cat | -0.5 | 2.7 | 1.0 | 1.0 | -0.9 | |
+/-B’mrk | - | - | - | 1.6 | -1.1 | |
Category: UK Large-Cap Equity | ||||||
Category Benchmark: Morningstar UK All Cap TME ... |
Key Stats | ||
NAV 22/04/2024 | GBX 154.47 | |
Day Change | 2.11% | |
Morningstar Category™ | UK Large-Cap Equity | |
IA (formerly IMA) Sector | UK All Companies | |
ISIN | GB00B9J7KW65 | |
Fund Size (Mil) 28/03/2024 | GBP 536.49 | |
Share Class Size (Mil) 22/04/2024 | GBP 33.47 | |
Max Initial Charge | - | |
Ongoing Charge 16/02/2024 | 0.80% |
Investment Objective: WS Canlife UK Equity Fund C Accumulation |
To achieve capital growth, over any five year period, after all costs and charges have been taken. To invest directly and/or indirectly at least 80% of the assets by value in the shares of companies which are incorporated or domiciled in the United Kingdom. As part of the equities exposure the Sub-fund may also invest in Real Estate Investment Trusts (REITs). |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Nigel Kennett 21/10/2013 | ||
Rino Shala 01/01/2019 | ||
Inception Date 18/10/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
Bloomberg UK L&M&S Cap TR GBP | Morningstar UK All Cap TME NR GBP |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for WS Canlife UK Equity Fund C Accumulation | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
AstraZeneca PLC | Healthcare | 8.52 |
Shell PLC | Energy | 7.34 |
Unilever PLC | Consumer Defensive | 5.72 |
GSK PLC | Healthcare | 4.15 |
BP PLC | Energy | 3.60 |
Increase Decrease New since last portfolio | ||
WS Canlife UK Equity Fund C Accumulation |